Skip to main content
Erschienen in: International Journal of Hematology 1/2017

03.10.2016 | Case Report

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

verfasst von: Valentina Marchica, Fabrizio Accardi, Paola Storti, Cristina Mancini, Eugenia Martella, Benedetta Dalla Palma, Marina Bolzoni, Katia Todoerti, Magda Marcatti, Chiara Schifano, Sabrina Bonomini, Gabriella Sammarelli, Antonino Neri, Maurilio Ponzoni, Franco Aversa, Nicola Giuliani

Erschienen in: International Journal of Hematology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The skin is a possible site of extramedullary localization in multiple myeloma (MM) patients; however, the mechanisms involved in this process are poorly understood. We describe the case of a refractory MM patient who developed a cutaneous localization under bortezomib treatment and we further expanded observations in other eight MM patients. We focused on the expression of genes involved in plasma cell skin homing, including CCR10, which was highly expressed. Moreover, we observed a lack of CXCR4 surface expression and the down-regulation of ICAM1/CD54 throughout the progression of the disease, suggesting a possible mechanism driving the escape of MM cells from the bone marrow into the skin.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109:2708–17.PubMedPubMedCentral Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109:2708–17.PubMedPubMedCentral
2.
Zurück zum Zitat Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008;25:325–34.CrossRefPubMed Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis. 2008;25:325–34.CrossRefPubMed
4.
Zurück zum Zitat Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94:334–43.CrossRefPubMed Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94:334–43.CrossRefPubMed
5.
Zurück zum Zitat Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805–12.CrossRefPubMed Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805–12.CrossRefPubMed
6.
Zurück zum Zitat Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–7.CrossRefPubMedPubMedCentral Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–7.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Wirk B, Wingard JR, Moreb JS. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transpl. 2013;48:10–8.CrossRef Wirk B, Wingard JR, Moreb JS. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transpl. 2013;48:10–8.CrossRef
9.
Zurück zum Zitat Requena L, Kutzner H, Palmedo G, Calonje E, Requena C, Perez G, et al. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. Arch Dermatol. 2003;139:475–86.CrossRefPubMed Requena L, Kutzner H, Palmedo G, Calonje E, Requena C, Perez G, et al. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases. Arch Dermatol. 2003;139:475–86.CrossRefPubMed
10.
Zurück zum Zitat Floyd SR, Pantanowitz L, McDermott DF, Yannucci J, Driver JA, Stevenson MA, et al. Plasma cell problems: case 1. disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. J Clin Oncol. 2005;23:3138–40.CrossRefPubMed Floyd SR, Pantanowitz L, McDermott DF, Yannucci J, Driver JA, Stevenson MA, et al. Plasma cell problems: case 1. disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. J Clin Oncol. 2005;23:3138–40.CrossRefPubMed
11.
Zurück zum Zitat Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003;170:1136–40.CrossRefPubMed Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003;170:1136–40.CrossRefPubMed
12.
Zurück zum Zitat Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRefPubMed Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–73.CrossRefPubMed
13.
Zurück zum Zitat Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, et al. Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget. 2016;7:2367–78.PubMed Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, et al. Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients. Oncotarget. 2016;7:2367–78.PubMed
14.
Zurück zum Zitat Sachdev R, George TI, Schwartz EJ, Sundram UN. Discordant immunophenotypic profiles of adhesion molecules and cytokines in acute myeloid leukemia involving bone marrow and skin. Am J Clin Pathol. 2012;138:290–9.CrossRefPubMed Sachdev R, George TI, Schwartz EJ, Sundram UN. Discordant immunophenotypic profiles of adhesion molecules and cytokines in acute myeloid leukemia involving bone marrow and skin. Am J Clin Pathol. 2012;138:290–9.CrossRefPubMed
15.
Zurück zum Zitat Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, et al. CCL27–CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157–65.CrossRefPubMed Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, et al. CCL27–CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157–65.CrossRefPubMed
16.
Zurück zum Zitat Fujita Y, Abe R, Sasaki M, Honda A, Furuichi M, Asano Y, et al. Presence of circulating CCR10 + T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides. Clin Cancer Res. 2006;12:2670–5.CrossRefPubMed Fujita Y, Abe R, Sasaki M, Honda A, Furuichi M, Asano Y, et al. Presence of circulating CCR10 + T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides. Clin Cancer Res. 2006;12:2670–5.CrossRefPubMed
17.
Zurück zum Zitat Varga C, Xie W, Laubach J, Ghobrial IM, O’Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169:843–50.CrossRefPubMed Varga C, Xie W, Laubach J, Ghobrial IM, O’Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169:843–50.CrossRefPubMed
18.
Zurück zum Zitat Blade J, Fernandez de Larrea C, Rosinol L. Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol. 2015;169:763–5.CrossRefPubMed Blade J, Fernandez de Larrea C, Rosinol L. Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol. 2015;169:763–5.CrossRefPubMed
19.
Zurück zum Zitat Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116:273–7.CrossRefPubMed Dahl IM, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002;116:273–7.CrossRefPubMed
20.
Zurück zum Zitat Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013;27:2075–7.CrossRefPubMedPubMedCentral Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013;27:2075–7.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231–42.CrossRefPubMed Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231–42.CrossRefPubMed
22.
Zurück zum Zitat Chang TP, Poltoratsky V, Vancurova I. Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol. 2015;194:2942–53.CrossRefPubMedPubMedCentral Chang TP, Poltoratsky V, Vancurova I. Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol. 2015;194:2942–53.CrossRefPubMedPubMedCentral
Metadaten
Titel
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
verfasst von
Valentina Marchica
Fabrizio Accardi
Paola Storti
Cristina Mancini
Eugenia Martella
Benedetta Dalla Palma
Marina Bolzoni
Katia Todoerti
Magda Marcatti
Chiara Schifano
Sabrina Bonomini
Gabriella Sammarelli
Antonino Neri
Maurilio Ponzoni
Franco Aversa
Nicola Giuliani
Publikationsdatum
03.10.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2104-1

Weitere Artikel der Ausgabe 1/2017

International Journal of Hematology 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.